<DOC>
	<DOCNO>NCT02148783</DOCNO>
	<brief_summary>Deficits memory , attention , cognitive , executive function common disability traumatic brain injury ( TBI ) . Dopamine ( DA ) neurotransmission implicate neural function dopaminergic pathway recognize frequently disrupt TBI . One widely use DAergic drug methylphenidate ( Ritalin® ) . Methylphenidate increase synaptic DA level bind presynaptic dopamine transporter ( DAT ) block re-uptake . PET methylphenidate challenge measure tonic DA release provide valuable insight molecular basis attention-deficit hyperactivity disorder ( ADHD ) addiction , well practical information regard likely effectiveness therapy ( 1 ) . The objective study use PET image [ 11C ] -raclopride , D2/D3 receptor ligand , administer methylphenidate , measure endogenous DA release patient experience problem cognition , attention executive function chronic stage TBI . In addition , use TMS test short intracortical inhibition , gamma-aminobutyric acid receptor A ( GABAA ) - mediate phenomenon , partial DA control , measure dopaminergic activity methylphenidate .</brief_summary>
	<brief_title>Dopamine Receptor Imaging Predict Response Stimulant Therapy Chronic TBI</brief_title>
	<detailed_description>- Males female ( n=30 ) , age 18 55 year chronic stage TBI experience deficit neuropsychological function TBIs incur 6 month injury , recruit military treatment facility civilian clinic present clinical management TBI post-concussive symptom . - 1 . Study participant evaluate use brain MRI , psychometric measure adapt TBI Common Data Elements , attention test information detail injury experience post-concussive symptom record . Transcranial magnetic stimulation ( TMS ) placebo methylphenidate ( 60 mg mouth ) challenge perform predict stimulant response . - 2 . Subjects study [ 11C ] -raclopride PET two imaging session . One session administration placebo methylphenidate , 60 mg mouth . Both placebo methylphenidate give 60 minute prior injection [ 11C ] -raclopride allow peak uptake methylphenidate brain . The bind potential [ 11C ] -raclopride relative non-displaceable reference region ( cerebellum ) , BPND , use measure D2/D3 receptor availability . The difference BPND methylphenidate placebo ( ΔBPND ) use measure tonic DA release . - 3 . Subjects treat oral methylphenidate , use force titration dose 30 mg give twice daily 4 week . At point , neuropsychologic test repeat . - Outcome measure : The primary outcome change information process speed neuropsychologic testing .</detailed_description>
	<mesh_term>Brain Injuries</mesh_term>
	<mesh_term>Central Nervous System Stimulants</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agents</mesh_term>
	<criteria>Age 18 55 year , inclusive A history sustain moderate severe TBI &gt; 6 month prior enrollment . Evidence one follow 3 criterion : 1 . GCS 3 12 ( GCS obtain Emergency Room note medical record ) 2 . Posttraumatic amnesia &gt; 24 hour 3 . TBIrelated abnormality neuroimaging ( either CT MRI ) . Persistent postconcussive symptom , accord DSMIV Research Criteria PostConcussional Disorder , include : 1 . Difficulty attention memory . 2 . One follow symptom , start shortly trauma persist least three month : 1 . Fatigability 2 . Disordered sleep 3 . Changes personality 4 . Apathy lack spontaneity 3 . Symptoms criterion ( ) ( b ) must onset trauma , significant worsen preexist symptom trauma . 4 . Disturbance symptoms cause significant impairment social occupational functioning represent significant decline previous level functioning . Ability read , write , speak English Ability give inform consent . Evidence penetrate brain injury . Contraindication methylphenidate therapy : 1 . Known glaucoma ( consistently raise intraocular pressure without associate optic nerve damage ) 2 . Motor tics family history Tourette 's syndrome ( diagnose presence multiple motor one vocal tic period year , three consecutive ticfree month ) 3 . Known hypersensitivity methylphenidate ( hive , difficulty breathing , swell face , lip , tongue , throat ) . 4 . Known severe anxiety restlessness prevents day day activity . 5 . Known preexist hypertension , heart failure , myocardial infarction , ventricular arrhythmia . 6 . Known preexist psychosis , bipolar illness . 7 . History seizure , interictal epileptiform discharge ( IEDs ) EEG absence seizure . 8 . Known peripheral vasculopathy , include Raynaud 's phenomenon . 9 . History drug dependence alcoholism . 10 . Concomitant treatment coumadin anticoagulant , anticonvulsant ( e.g. , phenobarbital , phenytoin , primidone ) , tricyclic drug ( e.g. , imipramine , clomipramine , desipramine ) . 11 . Concomitant therapy monoamine oxidase inhibitor ( Marplan ( isocarboxazid ) , Nardil ( phenelzine ) , Emsam ( selegiline ) , Parnate ( tranylcypromine ) ) 12 . Concomitant treatment blood pressure medication ( high low blood pressure ) . 13 . Pregnancy 14 . Breastfeeding History evidence disable preexist coexist disable neurologic psychiatric disorder related TBI , : 1 . Multiple sclerosis , pre coexist 2 . Stroke ( stroke time TBI ) 3 . Preexisting disable developmental disorder 4 . Preexisting epilepsy 5 . Preexisting major depressive disorder , aggressive behavior , hostility 6 . Preexisting schizophrenia Contraindication MRI scan 1 . Ferromagnetic metal cranial cavity eye , e.g. , aneurysm clip , implanted neural stimulator , cochlear implant , ocular foreign body 2 . Implanted cardiac pacemaker autodefibrillator pump 3 . Nonremovable body pierce 4 . Claustrophobia 5 . Inability lie supine two hour Contraindication TMS , metal cranial cavity implant electronic hardware . Current participation interventional clinical trial Nonadherence use effective method contraception females able become pregnant time enrollment study 2 week completion study drug . Present history alcohol substance abuse disorder determine DSMIV Body mass index ( BMI ) &gt; 30</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Traumatic brain injury</keyword>
	<keyword>Attention deficit memory problem</keyword>
	<keyword>Methylphenidate</keyword>
	<keyword>Dopamine receptor image</keyword>
	<keyword>Motivation reward</keyword>
	<keyword>Positron emission tomography</keyword>
	<keyword>Transcranial magnetic stimulation</keyword>
</DOC>